Table 2.
Demographic, clinical disease characteristics, and medication history of the patients in CD patients.
| North-American | Chilean | P value | |
|---|---|---|---|
| N | 23 16 (70%) Caucasian/4 (17%) Hispanic-Latin/2 (9%) another Pacific Island/1 (4%) Asian |
69 68 (99%) Latin/1 (1%) Latin-Mapuche |
.5725 |
| Age, yr, median (max–min) | 45 (27–67) | 44 (19–80) | NS |
| Duration of disease, yr, mean (max–min) | 16 (1–44) | 6 (0–26) | .04 |
| Age at diagnosis, yr, mean (max–min) | 24 (11–58) | 37 (14–67) | .005 |
| Sex | 7 (30%) female/16 (70%) male | 40 (58%) female/27 (39%) male | .01 |
| Smoking (yes/no/no data) | 4 (17%)/16 (70%)/3 (13%) | 14 (20%)/51 (74%)/4 (6%) | NS |
| Surgery (yes/no) | 9 (39%)/14 (61%) | 16 (23%)/53 (77%) | NS |
| History of hospitalization (yes/no/no data) | 16 (70%)/4 (17%)/3 (13%) | 36 (52%)/31 (45%)/2 (3%) | .04 |
| Family history of IBD (yes/no) | 3 (13%)/20 (87%) | 6 (8.7%)/63 (91.3%) | NS |
| Montreal Crohn disease | |||
| A1/A2/A3/No data | 2/15/2/4 | 4/40/25/0 | .0008 |
| Ileal (L1) | 2 (9%) | 18 (26%) | .0002 |
| Colonic (L2) | 4 (17%) | 35 (51%) | |
| Ileocolonic (L3) | 17 (74%) | 16 (23%) | |
| Upper compromise (L4) | 2 (9%) | 8 (11.6%) | |
| B1 (inflammatory) | 9 (39%) | 37 (54%) | NS |
| B2 (structuring) | 11 (48%) | 17 (25%) | |
| B3 (penetrating) | 3 (13%) | 15 (21%) | |
| Perianal disease (yes/no) | 9 (39%)/14 (61%) | 14 (20)/55 (80%) | NS |
| White cells ×106/L (normal range 4000–11,000), median (max–min) | 7450 (4800–12,700) | 6750 (1640–15,450) | NS |
| Hemoglobin (g/L) (normal range 12–18), median (max–min) | 12.35 (7.7–15.7) | 12.65 (8.8–17.2) | NS |
| Platelets ×106/L (normal range 150,000–450,000), mean (max–min) | 271,500 (155,000–699,000) | 292,000 (140,000–629,000) | NS |
| C reactive protein (mg/dL) normal range < 0.5 | 4 (0.03–1.6) | 7 (0.05–8.1) | .01 |
| Erythrocyte sedimentation rate (mm/h) normal range < 30 | 11 (2–71) | 11 (2–47) | NS |
| Albumin (g/L) normal range (3.5–5.5) | 4.1 (2.9–4.9) | 4.4 (2.9–5.1) | .0006 |
| Harvey-Bradshaw Index | 2 (0–9) | 3 (0–18) | NS |
| SES-CD | 0 (0–19) | 4 (0–21) | .001 |
| Current therapies (yes/no) | |||
| Steroids | 2 (9%)/21 (91%) | 15 (22%)/54 (78%) | NS |
| Biological | 20 (87%)/3 (13%) | 16 (23%)/53 (77%) | .0001 |
| Inmunomodulators | 13 (6%)/10 (94%) | 24 (35%)/45 (65%) | NS |
| History of therapies (yes/no) | |||
| Steroids | 19 (83%)/4 (17%) | 52 (75%)/17 (25%) | NS |
| Inmunomodulators | 19 (83%)/4 (17%) | 48 (70%)/21 s(30%) | NS |
| Naive anti-TNF | 1 (4%)/22 (96%) | 48 (70%)/21 (30%) | <.0001 |
CD = Crohn disease, IBD = inflammatory bowel disease, NS = not significant, SES-CD = simple endoscopic score for Crohn’s disease.